Catalyst
The FDA recently cleared MRidium® 3870 Infusion Pump System by Iradimed Corporation, which could drive positive momentum for the medical device sector including ZTS.
Risk
Technical indicators show that the market is in a weak state and bearish signals are clearly dominant, increasing the risk of further decline for ZTS.
Fund flow analysis indicates a negative overall trend with small and medium-sized fund outflows, suggesting reduced investor confidence in ZTS.
Analysts have issued only a Neutral rating for ZTS, reflecting a lack of strong institutional optimism or bullish sentiment for the stock.
Generated at21:3102/06/2026by
Aime